Identification and Characterization of MAVS, a Mitochondrial Antiviral Signaling Protein that Activates NF-κB and IRF3  by Seth, Rashu B. et al.
Cell, Vol. 122, 669–682, September 9, 2005, Copyright ©2005 by Elsevier Inc. DOI 10.1016/j.cell.2005.08.012
Identification and Characterization of MAVS,
a Mitochondrial Antiviral Signaling Protein
that Activates NF-B and IRF3
Rashu B. Seth,1 Lijun Sun,1 Chee-Kwee Ea,
and Zhijian J. Chen*
Howard Hughes Medical Institute
Department of Molecular Biology
University of Texas Southwestern Medical Center
Dallas, Texas 75390
Summary
Viral infection triggers host innate immune responses
through activation of the transcription factors NF-B
and IRF3, which coordinately regulate the expression
of type-I interferons such as interferon- (IFN-).
Herein, we report the identification of a novel protein
termed MAVS (mitochondrial antiviral signaling), which
mediates the activation of NF-B and IRF3 in re-
sponse to viral infection. Silencing of MAVS expres-
sion through RNA interference abolishes the activa-
tion of NF-B and IRF3 by viruses, thereby permitting
viral replication. Conversely, overexpression of MAVS
induces the expression of IFN- through activation
of NF-B and IRF3, thus boosting antiviral immunity.
Epistasis experiments show that MAVS is required for
the phosphorylation of IRF3 and IB and functions
downstream of RIG-I, an intracellular receptor for viral
RNA. MAVS contains an N-terminal CARD-like domain
and a C-terminal transmembrane domain, both of
which are essential for MAVS signaling. The trans-
membrane domain targets MAVS to the mitochondria,
implicating a new role of mitochondria in innate im-
munity.
Introduction
Viral infection of host cells triggers innate and adaptive
immune responses that are essential for the survival of
the host. A highly effective antiviral immune response
is the production of type-I interferons, such as in-
terferon-α (IFN-α) and interferon-β (IFN-β). These in-
terferons activate the JAK-STAT pathway to stimulate
the expression of interferon-stimulated genes (ISGs),
which collectively inhibit viral replication and assembly
(Darnell et al., 1994). The genes encoding interferons
are regulated by the assembly of an enhanceosome
containing several transcription factors including NF-
κB and IRF3, both of which are regulated by subcellular
localization (Maniatis et al., 1998). In unstimulated cells,
NF-κB is sequestered in the cytoplasm in association
with an inhibitor of the IκB family (Baeuerle and Balti-
more, 1988). Stimulation of cells with cytokines (e.g.,
TNFα or IL-1β) or pathogens (e.g., bacteria or viruses)
leads to the activation of a large kinase complex con-
sisting of the catalytic subunits IKKα and IKKβ and the
essential regulatory subunit NEMO (also known as IKKγ
or IKKAP). The activated IKK complex phosphorylates*Correspondence: zhijian.chen@utsouthwestern.edu
1These authors contributed equally to this work.IκB and targets this inhibitor for degradation by the
ubiquitin-proteasome pathway. NF-κB is then liberated
to enter the nucleus to turn on a battery of genes
essential for immune and inflammatory responses (Sil-
verman and Maniatis, 2001).
Similar to NF-κB, IRF3 is also retained in the cyto-
plasm of unstimulated cells. After viral or bacterial in-
fection of cells, IRF3 is phosphorylated at multiple ser-
ine and threonine residues at the C terminus (Hiscott et
al., 2003; Yoneyama et al., 2002). The phosphorylated
IRF3 then homodimerizes and enters the nucleus to ac-
tivate IFN-β in a highly cooperative manner with NF-
κB. The kinases that phosphorylate IRF3 have recently
been identified as the IKK-like kinases TBK1 and IKK
(Fitzgerald et al., 2003; Sharma et al., 2003). Genetic
experiments have shown that TBK1 is important for in-
terferon production by the bacterial cell wall compo-
nent lipopolysaccharides (LPS) as well as viruses
(Hemmi et al., 2004; McWhirter et al., 2004). In some
cells, however, the function of TBK1 may be compen-
sated by IKK or other kinases (Perry et al., 2004; Yo-
neyama et al., 2004). TBK1 and IKK can also phos-
phorylate and activate IRF7 (tenOever et al., 2004),
another IRF family member essential for the production
of type-I interferons such as interferon-α (Honda et al.,
2005).
Both NF-κB and IRFs are tightly regulated by micro-
bial pathogens, including RNA viruses. After entry into
host cell and uncoating of an RNA virus, the viral RNA
replicates to produce double-stranded RNA intermedi-
ates, which are recognized by the host as a pathogen-
associated molecular pattern (PAMP). Several proteins
that recognize viral RNA have been discovered, includ-
ing Toll-like receptors TLR3, 7, and 8 (Akira and Takeda,
2004). TLR3 contains an intracellular Toll-interleukin re-
ceptor (TIR) domain that signals to NF-κB and IRF3 via
the adaptor protein TRIF (Akira and Takeda, 2004),
whereas the TIR domain of TLR7 and TLR8 binds to
another adaptor MyD88, which associates with and ac-
tivates IRF7 to induce interferon-α (Kawai et al., 2004).
In addition, TLRs contain several extracellular leucine-
rich repeats (LRRs) that presumably recognize micro-
bial ligands. Thus, the topology of these receptors dic-
tates that they can only recognize extracellular dsRNA
or single-stranded RNA associated with viral particles
that are internalized into the endosomes (Crozat and
Beutler, 2004). The receptor that detects intracellular
dsRNA generated by the virus is a newly identified pro-
tein RIG-I, which contains two N-terminal CARD-like
domains, and a C-terminal RNA helicase domain that
binds to dsRNA (Sumpter et al., 2005; Yoneyama et al.,
2004). Presumably, the binding of viral RNA to RIG-I
leads to a conformational change that exposes the
CARD-like domain, which then activates downstream
signaling. Consistent with this model, overexpression
of the N-terminal CARD-like domains of RIG-I is suffi-
cient to activate both NF-κB and IRF3 (Yoneyama et al.,
2004). However, the mechanism by which RIG-I acti-
vates NF-κB and IRF3 is currently not understood. A
RIG-I-like protein MDA-5 (also known as HELICARD),
Cell
670which also contains two CARD-like domains and an
RNA helicase domain, has recently been shown to be
involved in dsRNA signaling and apoptosis (Andrejeva
et al., 2004; Kang et al., 2002; Kovacsovics et al., 2002).
However, MDA-5 does not appear to function redun-
dantly with RIG-I in the antiviral pathway, as an inacti-
vating mutation of RIG-I or the loss of RIG-I expression
completely blocks interferon production by several
RNA viruses (Kato et al., 2005; Sumpter et al., 2005;
Yoneyama et al., 2004).
Here, we report the identification of a novel protein
that is essential for NF-κB and IRF3 activation by RNA
viruses. This protein, named MAVS (mitochondrial anti-
viral signaling), contains an N-terminal CARD-like do-
main and a C-terminal transmembrane domain that tar-
gets the protein to the mitochondrial membrane. MAVS
functions downstream of RIG-I and upstream of IκB
and IRF3 phosphorylation. Suppression of MAVS ex-
pression blocked interferon production and exacer-
bated the viral replication and killing of the host cells.
Conversely, overexpression of MAVS augmented in-
terferon production and conferred antiviral immunity.
Deletion of the CARD-like domain of MAVS abolished
its signaling function and converted it into a dominant-
negative mutant that inhibited interferon induction. Im-
portantly, the mitochondrial targeting transmembrane
domain is also essential for MAVS signaling, thus impli-
cating a new role of mitochondria in innate immunity.
Results
Identification and Sequence Analysis of MAVS
To understand the signaling pathways required for the
activation of NF-κB and IRF3 by viruses, we sought to
identify proteins containing CARD-like domains similar
to those of RIG-I and its homolog MDA-5. A BLAST
search with the first CARD-like domain of MDA-5 iden-
tified an uncharacterized protein KIAA1271, which con-
tains a single CARD-like domain at the N terminus. In-
terestingly, this protein was also identified as a putative
NF-κB activator in a large-scale screening for proteins
that can activate an NF-κB reporter when they are over-
expressed (Matsuda et al., 2003). However, there was
no further characterization of this protein concerning
its domain structure, activity, or biological function. We
have analyzed the sequence of this protein, and found
that in addition to the N-terminal CARD-like domain,
which is conserved from pufferfish to human (Figures
1A–1C), KIAA1271 also contains a proline-rich region in
the middle and a hydrophobic transmembrane domain
at the C terminus (Figure 1D). The transmembrane do-
main was predicted using two different programs:
TMpred (http://www.ch.embnet.org/software/TMPRED_
form.html; Figure 1D), and Kyte-Doolittle hydropathy
plot (data not shown). As will be shown later (Figure 7),
this transmembrane domain targets KIAA1271 to the
mitochondria. We therefore designated this protein as
mitochondrial antiviral signaling (MAVS) protein.
MAVS Activates NF-B, IRF3, and IRF7
to Induce Interferons
Although overexpression of many proteins can activate
NF-κB, a much smaller number of proteins can activate
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toth NF-κB and IRF3, which are required for the induc-
ion of interferons. We therefore tested whether MAVS
ould activate a luciferase reporter that is under the
ontrol of the IFN-β promoter. This promoter contains
nhancer elements that bind to several transcription
actors including NF-κB, IRF3, and ATF2. The coordi-
ate activation of all of these transcription factors is
equired for the formation of an enhanceosome that ac-
ivates IFN-β. Significantly, overexpression of MAVS in
EK293 cells potently activates the IFN-β promoter
Figure 2A). In control experiments, infection of the
ame cells with the Sendai virus (S.V.), an RNA virus of
he paramyxoviridae family, leads to the activation of
FN-β. Similarly, overexpression of the tandem N-ter-
inal CARD-like domains of RIG-I (designated as RIG-
(N)) also induces IFN-β. In contrast, overexpression of
nother CARD domain protein RIP2 (Inohara et al.,
998), which is known to activate NF-κB but not IRF3
n response to intracellular bacterial infection, failed to
nduce IFN-β. Consistent with the ability of MAVS to
nduce the assembly of the IFN-β enhanceosome,
AVS activated both IRF3 (Figure 2B) and NF-κB (Fig-
re 2C). In the former case, the activation of IRF3 was
easured by the phosphorylation and dimerization of
chimeric protein consisting of IRF3 fused to the DNA
inding domain of Gal4, which drives the expression of
he luciferase reporter gene. In the latter case, NF-κB
ctivation was measured using a luciferase reporter
hose expression was driven by three copies of an NF-
B enhancer. We also examined whether MAVS acti-
ates JNK, which is known to phosphorylate and acti-
ate ATF2. Similar to RIP2, overexpression of MAVS led
o the activation of JNK, as measured by immunoblot-
ing with an antibody specific for phosphorylated JNK
see Figure S1A in the Supplemental Data available with
his article online). Overexpression of MAVS also in-
uced the production of endogenous IFN-β, as deter-
ined by ELISA of culture supernatants (Figure 2D). RT-
CR experiments showed that MAVS induced IFN-β
nd the chemokine RANTES, but not the housekeeping
ene GAPDH, at the RNA level (Figure 2E). Immunoblot-
ing experiments showed that MAVS activated IRF3 by
nducing the phosphorylation (Figure 2F, upper panel)
nd dimerization of IRF3 (Figure 2F, lower panel). To
etermine if MAVS also activates IRF7, a master regula-
or of IFN-α, we cotransfected MAVS, IRF7, and an
FN-α luciferase reporter into HEK293 cells, which do
ot express endogenous IRF7. Similar to Sendai virus
nfection, overexpression of MAVS or RIG-I(N) potently
nduced IFN-α promoter activity (Figure S1B). Collec-
ively, these results show that MAVS is a potent activa-
or of IRF3, IRF7, and NF-κB and that its overexpres-
ion is sufficient to mimic viral infection to induce
ytokines including IFN-α, IFN-β, and RANTES.
AVS Is Required for IKK and IRF3 Activation
nd IFN- Induction by Sendai Virus
o determine if MAVS is required for IFN-β induction
y viruses, we used RNAi to silence the expression of
ndogenous MAVS, which was detected with an affin-
ty-purified MAVS antibody against a fragment of MAVS
ontaining amino acids 131–291. This antibody de-
ected multiple bands in whole-cell lysates derived
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671Figure 1. Domain and Sequence Analyses of MAVS
(A) A schematic diagram of MAVS protein. TM: transmembrane domain.
(B) Sequence alignment of the CARD-like domains of MAVS, RIG-I and MDA-5, using the Clustal W program.
(C) Sequence alignment of the CARD-like domains of MAVS from different species based on the genome projects. The asterisk (*) indicates
the residues that were mutated to alanine in Figure 6A.
(D) Prediction of the MAVS transmembrane domain using the TMpred server. A score of greater than 500 predicts a transmembrane region.from HEK293 cells as well as those transfected with
the control GFP siRNA oligos (Figure 3A, lower panel).
These bands disappeared in cells transfected with two
different pairs of siRNA oligos targeting distinct regions
of MAVS, indicating that the bands detected by the an-
tibody were indeed MAVS proteins. It is not clear why
MAVS protein exists as multiple bands on SDS-PAGE,
but it is unlikely that they represent different spliced
variants, as the same expression pattern was observed
when cells were transfected with MAVS cDNA (data notshown). The pattern of these bands did not change
when cell extracts were treated with phosphatases or
glycosidase (data not shown), suggesting that they are
not the phosphorylated or glycosylated forms of MAVS.
We have also been unable to obtain evidence of MAVS
modification by ubiquitin or ubiquitin-like proteins such
as ISG-15. Thus, it is likely that the lower bands repre-
sent the degradation or processing products of MAVS,
whereas the upper band is the full-length MAVS protein.
The MAVS protein bands were detected by immu-
Cell
672Figure 2. MAVS Is a Potent Inducer of IFN-β
(A) Increasing amounts of expression vectors for MAVS, RIG-I(N), and RIP2 were transfected into HEK293 cells together with an IFNβ-
luciferase reporter as well as pCMV-LacZ as an internal control. Thirty-six hours after transfection, the luciferase activity was measured and
normalized based on β-galactosidase activity. The error bars represent the standard deviation from the mean value obtained from duplicated
experiments. S.V.: cells transfected with IFNβ-Luc were infected with Sendai virus for 20 hr.
(B) The experiments were carried out as in (A), except that Gal4-Luc and Gal4-IRF3 plasmids were cotransfected together in lieu of IFNβ-Luc.
(C) Similar to (A), except that p-κB3-tk-Luc was transfected in lieu of INFβ-Luc.
(D) HEK293 cells were transfected with the expression vectors for MAVS (500 ng), RIG-I(N; 200 ng), RIP2 (500 ng), the vector pcDNA3 (500
ng), or infected with Sendai virus (S.V.; 50 HA units/ml). Thirty-six hours after transfection or 20 hr after viral infection, the culture supernatant
was collected to measure IFN-β production by ELISA.
(E) An aliquot of the cell pellet from (D) was lysed to isolate RNA for RT-PCR using primers specific for IFN-β, the chemokine RANTES, and
GAPDH (as a control).
(F) After transfection or viral infection as described in (D), HEK293 cells were lysed to prepare protein extracts, which were then resolved by
SDS-PAGE (upper panel) or native gel electrophoresis (lower panel). Phosphorylation or dimerization of IRF3 was detected by immunoblotting
(IB) with an IRF3 antibody.noblotting in multiple human cell lines (Figure S2), in-
cluding Jurkat (T cell), U937 (monocyte), Huh7 (hepato-
cyte), A549 (lung epithelial cell), and HeLa (cervical
epithelial cell). Thus, MAVS is expressed in many dif-
ferent cell types, especially those that constitute the
first line of defense against viruses, such as liver and
lung cells.
Strikingly, both pairs of MAVS siRNA oligos abolished
IFN-β induction by Sendai virus (Figure 3A, upper
panel). Since the sequences of these two pairs of RNA
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dligos are very different, it is exceedingly unlikely that
hey silence a common “off-target” gene responsible
or IFN-β induction. Further supporting this conclusion,
e found that a MAVS expression vector containing a
ilent mutation that renders MAVS resistant to RNAi
as able to rescue IFN-β induction in the MAVS RNAi
ells (data not shown). As controls, RNAi of RIG-I, but
ot GFP, also blocked viral induction of INF-β (Figure
A). Similarly, RNAi of MAVS or RIG-I blocked the pro-
uction of endogenous IFN-β protein by Sendai virus,
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673Figure 3. MAVS Is Required for IFN-β Induction by Sendai Virus
(A) siRNA oligos targeting GFP (control), RIG-I, and two different regions of MAVS (a and b) were transfected into HEK293 cells to silence the
expression of endogenous proteins. The efficiency of MAVS RNAi was confirmed by immunoblotting with a MAVS-specific antibody (bottom
panel). To measure IFNβ induction, the IFNβ-Luc reporter plasmid was transfected into the RNAi cells, which were then infected with Sendai
virus for 20 hr followed by luciferase assays (upper panel).
(B) The siRNA transfection into HEK293 cells and viral infection were carried out as in (A), and the supernatant was collected for measurement
of IFN-β by ELISA.
(C) Similar to (B), except that cells were lysed to isolate RNA for RT-PCR.
(D) Similar to (B), except that protein extracts were prepared from the cells and analyzed for IRF3 phosphorylation by SDS-PAGE (upper
panel) or dimerization by native gel electrophoresis (lower panel).
(E) MAVS is required for IKK activation by Sendai virus. HEK293 cells expressing the full-length RIG-I, which facilitates the activation of IKK
and IRF3 by Sendai virus, were transfected with siRNA oligos for GFP or MAVS. These cells were then stimulated with TNFα (10 ng/ml) or
infected with Sendai virus (50 HA units/ml) for the indicated time before cell lysates were prepared. An aliquot of the cell lysates (20 g) was
immunoblotted with a MAVS antibody (lower panel). Five hundred micrograms of the cell lysates were immunoprecipitated with an antibody
against NEMO to isolate the IKK complex, whose activity was measured using GST-IκBα and γ-32P-ATP as substrates (upper panel). An
aliquot of the IKK immunoprecipitate was immunoblotted with an IKKβ antibody (middle panel).
(F) MAVS is required for IFN-β induction by double-stranded RNA. HEK293-RIGI cells were transfected with siRNA oligos targeting GFP,
RIG-I, or MAVS as described in (A). Subsequently, cells were transfected with 0.5 g of poly(I:C) or pcDNA3 (as control) together with the
IFNβ-Luc and pCMV-LacZ plasmids. Luciferase assays were performed 48 hr after transfection.as measured by ELISA (Figure 3B). RT-PCR analyses
showed that viral induction of IFN-β and RANTES RNA
was abolished in the absence of MAVS or RIG-I (Figure
3C). Furthermore, RNAi of MAVS or RIG-I prevented the
phosphorylation (Figure 3D, upper panel) and dimeriza-
tion (Figure 3D, lower panel) of IRF3 induced by Sendai
virus, indicating that both MAVS and RIG-I are requiredfor IRF3 phosphorylation. To determine if MAVS is also
required for IKK activation by the virus, we carried out
an IKK kinase assay (Figure 3E). Since the activation
of IKK by Sendai virus is much slower and weaker as
compared to TNFα stimulation, we transfected HEK293
cells with an expression construct encoding the full-
length RIG-I protein, which potentiated the activation
Cell
674of IKK such that IKK activity was detectable within 4 hr
of viral infection (Figure 3E, lanes 3–6). Importantly,
RNAi of MAVS blocked IKK activation by Sendai virus,
but not TNFα. To determine if MAVS is required for in-
terferon-β induction by dsRNA, we transfected poly(I:C)
into a HEK293 cell line stably expressing the full-length
RIG-I protein. The transfected poly(I:C) is known to
mimic viral dsRNA to bind to RIG-I and stimulate in-
terferon production. As shown in Figure 3F, knockdown
of MAVS expression with two different pairs of siRNA
oligos blocked IFN-β induction by poly(I:C), suggesting
that MAVS may be required for immune defense against
all RNA viruses that generate dsRNA in their life cycle.
Taken together, these results demonstrate that MAVS is
essential for viral activation of IKK and IRF3.
MAVS Is a Potent Antiviral Protein
Since MAVS is both necessary and sufficient for the
induction of type-I interferons, we examined whether
this protein could mediate immune defense against the
vesicular stomatitis virus (VSV), an RNA virus of the
rhabdoviridae family. Infection of HEK293 cells by VSV
led to nearly complete killing of the cells within 24 hr
at a multiplicity of infection (MOI) of 0.01 (Figure 4A).
Transfection of these cells with an expression vector
encoding FLAG-MAVS prevented cell killing by VSV
even at a MOI of 0.1. Conversely, silencing of the en-
dogenous MAVS expression by RNAi greatly sensitized
cell killing by VSV at a much lower MOI (0.001). Mea-
surement of the viral titer showed that overexpression
of FLAG-MAVS decreased the viral titer by more than
20-fold as compared to control cells (from 5.5 × 107 to
2.6 × 106 plaque-forming units [pfu] at 12 hr after infec-
tion; Figure 4B). Conversely, RNAi of MAVS led to an
increase of viral titer by 20-fold as compared to control
cells (from 5.5 × 107 to 1.1 × 109 pfu). These results
show that MAVS is a pivotal cellular antiviral protein
whose expression level directly determines antiviral im-
munity.
MAVS Functions Downstream of RIG-I
and Upstream of TBK1
As both RIG-I and MAVS function upstream of IKK and
IRF3 activation, we sought to determine the epistatic
relationship between these two proteins. As shown in
Figure 5A, RNAi of MAVS blocked IFN-β induction by
Sendai virus, or by overexpression of the N-terminal
fragment of RIG-I (RIG-I(N)) as well as MAVS itself. In
contrast, RNAi of RIG-I did not inhibit IFN-β induction
by the overexpression of MAVS. This pair of siRNA
oligos blocked INF-β induction by Sendai virus, but not
RIG-I(N), because the sequence targeted by the RNA
oligos was located at nucleotides 2363–2381, outside
the region encoding RIG-I(N). Similar to IFN-β, the IRF7-
mediated induction of IFN-α by Sendai virus also re-
quired RIG-I and MAVS (Figure 5B). Furthermore, RNAi
of MAVS blocked IFN-α activation by RIG-I(N). In con-
trast, RNAi of RIG-I did not affect IFN-α induction by
MAVS (Figure 5B). We conclude from these experi-
ments that MAVS functions downstream of RIG-I in the
antiviral signaling pathway.
Recent studies have shown that overexpression of
TRIF, TBK1, or IKK is sufficient to activate IFN-β and
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Tigure 4. MAVS Is a Potent Antiviral Protein
A) HEK293 cells were transfected with pcDNA3-FLAG-MAVS (0.5
g) or siRNA oligos (20 nM) targeting MAVS. Forty-eight hours after
ransfection, cells were infected with VSV at the indicated MOI for
4 hr. After fixing, cells that were not killed by the virus were
tained with Amido black.
B) The culture supernatant from cells infected with VSV at the MOI
f 0.01 were collected at the indicated time points, and the viral
iter was determined by plaque assay.hat TBK1 and IKK are the kinases that phosphorylate
RF3 at the C terminus. We therefore investigated the
elationship between MAVS and TRIF, TBK1, and IKK.
hile RNAi of MAVS abolished IFN-β induction by Sen-
ai virus, it had no effect on the activation of IFN-β by
RIF, TBK1, or IKK (Figure 5C). Consistent with previ-
us reports, RNAi of RIG-I did not affect IFN-β induction
y TRIF, TBK1, or IKK (Yoneyama et al., 2004). These
esults indicate that RIG-I and MAVS do not function
ownstream of TRIF, TBK1, or IKK. To determine if
BK1 or IKK functions downstream of MAVS, we at-
empted to knock down the expression of TBK1 and
KK by RNAi in HEK293 cells. We have tried nine dif-
erent pairs of TBK1 and five different pairs of IKK
iRNA oligos individually or in combination. Unexpect-
dly, none of the TBK1 and/or IKK siRNA oligos
locked IFN-β induction by MAVS or Sendai virus (data
ot shown). Since we cannot rule out the possibility
hat the RNAi experiments did not result in sufficient
nockdown of TBK1 or IKK protein, we turned to
BK1-deficient MEF cells, which are known to be de-
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675Figure 5. MAVS Functions Downstream of RIG-I and Upstream of
TBK1
(A) HEK293 cells were transfected with siRNA oligos targeting GFP,
RIG-I, or MAVS. These cells were subsequently transfected with
IFNβ-Luc together with expression vectors (300 ng) encoding the
N-terminal fragment of RIG-I [RIG-I(N)], MAVS, or empty vector
(pcDNA3). As a positive control, cells were infected with Sendaifamily that protect cells from undergoing apoptosis
virus (S.V.). Twenty hours after viral infection or 24 hr after transfec-
tion of the expression plasmids, cells were harvested for lucifer-
ase assays.
(B) Similar to (A) except that pIFNα4-Luc (40 ng) and pcDNA3-
FLAG-IRF7 (10 ng) were transfected into HEK293 cells to measure
the activation of IFNα by IRF7.
(C) Similar to (A) except that expression vectors (300 ng) for TRIF,
TBK1, and IKK were used.
(D) Wild-type or TBK1−/− MEF cells were transfected with pIFNα4-
Luc (300 ng) and pcDNA3-FLAG-IRF7 (50 ng) together with pEF-
HA-MAVS (100 ng) or control vector. For Sendai virus infection,
MEF cells transfected with the luciferase reporter plasmids were
infected with 50 HA units/ml of the virus.
(E) A proposed antiviral signaling pathway. In this pathway, MAVS
functions downstream of RIG-I and upstream of IKK and TBK1.fective in producing interferons in response to Sendai
virus infection. As shown in Figure 5D, infection of Sen-
dai virus or overexpression of MAVS induced IFN-α in
the wild-type MEF cells. In contrast, the IFN-α induc-
tion was greatly reduced in TBK1-deficient cells. Col-
lectively, the results shown in Figures 3D, 3E, and 5 de-
lineate a signaling pathway in which MAVS functions
downstream of RIG-I and upstream of IKK and TBK1
(Figure 5E).
The CARD-like Domain Is Essential
for MAVS Signaling
The N-terminal CARD-like domain of MAVS is evolu-
tionarily conserved (Figure 1C). In addition, MAVS con-
tains a proline-rich domain in the middle (Figure 1A). To
investigate the functions of these domains, we engi-
neered expression constructs encoding MAVS mutant
proteins lacking either the CARD-like domain (CARD)
or the proline-rich domain (PRO; Figure 6A). As shown
in Figures 6B and 6C, deletion of the CARD-like do-
main, but not the proline-rich domain, abolished the
ability of MAVS to activate IFN-β or NF-κB. Further-
more, a point mutation of a conserved threonine resi-
due to alanine (T54A) or simultaneous mutations of
three conserved residues in the CARD-like domain to
alanine (G67A/W68A/V69A, abbreviated as AAA) se-
verely impaired the ability of MAVS to activate IFN-β
(Figure 6D). These results indicate that an intact CARD-
like domain is essential for MAVS signaling. This con-
clusion was further supported by Figures 6E and 6F,
which showed that MAVS-CARD, but not MAVS-
PRO, functioned as a dominant-negative mutant that
inhibited the activation of IFN-β and NF-κB promoters
by Sendai virus. The CARD-like domain alone did not
function as a dominant-negative mutant (Figure S3),
suggesting that when the CARD-like domain is not teth-
ered to the rest of MAVS protein such as the membrane
domain, it may not interact effectively with other pro-
teins in the pathway.
The C-Terminal Transmembrane (TM) Domain
of MAVS Is Essential for Its Function
Notably, the C terminus of MAVS contains a conserved
hydrophobic transmembrane (TM) domain, which re-
sembles the TM domain of several tail-anchored mito-
chondrial proteins, including the proteins of the Bcl-2
Cell
676Figure 6. The CARD-like Domain Is Essential for MAVS Signaling
(A) A diagram illustrating the MAVS mutants. CARD: lacking residues 10–77; PRO: lacking residues 103–152; AAA: G67A/W68A/V69A.
(B–D) HEK293 cells were transfected with IFNβ-Luc or κB3-Luc together with expression vectors for MAVS and its mutants as indicated.
(E) The CARD mutant of MAVS is a dominant-negative inhibitor of IFN-β induction by Sendai virus. HEK293 cells were transfected with IFNβ-
Luc together with expression vectors for MAVS or its mutants. The cells were then infected with Sendai virus for 20 hr followed by measure-
ment of luciferase activity.
(F) Similar to (E), except that κB3-Luc was used in lieu of IFNβ-Luc.(Figure 7A, left panel; Kaufmann et al., 2003). To deter-
mine the function of this domain, we created a MAVS
mutant protein lacking the C-terminal TM domain
(MAVS-TM). This mutant protein completely lost its
ability to activate IFN-β (Figure 7A, right panel). Immu-
noblotting experiments showed that MAVS-TM was
abundantly expressed and became a soluble cytosolic
protein, whereas the full-length MAVS was present in
membrane pellets (data not shown; also see Figure 7C
for confocal image).
The CARD-like and TM Domains of MAVS Are
Sufficient to Induce IFN-
Since the most conserved regions of MAVS are the
N-terminal CARD-like domain and the C-terminal TM
domain, and each of these domains is necessary for
MAVS signaling, we examined whether these two do-
mains are sufficient to activate IFN-β expression. Re-
markably, the MAVS mutant containing only the CARD-
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wike and TM domains (N100 + TM) was sufficient to
nduce IFN-β (Figure 7B), whereas the mutants contain-
ng only the CARD-like domain were inactive. Thus, the
ARD-like and TM domains are both necessary and
ufficient for MAVS signaling.
AVS Is a Mitochondrial Membrane Protein
o determine the subcellular localization of MAVS, we
mployed confocal microscopy to image HeLa cells
ransfected with an expression vector encoding HA-
agged MAVS (Figure 7C, upper panel). Fluorescent
mmunostaining with an HA-specific antibody showed
punctate pattern of MAVS localization that over-
apped with the staining pattern of Mito Tracker, a fluo-
escent marker taken up specifically by mitochondria.
e also found by confocal microscopy that MAVS lack-
ng the C-terminal transmembrane domain (MAVS-
TM) was a cytosolic protein that no longer overlapped
ith Mito Tracker staining (Figure 7C, lower panel). As
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Bcl-2, which is localized to both endoplasmic reticulum
(ER) and mitochondria, we examined whether a fraction
of MAVS might be localized to ER. As shown in Figure
S4A, the staining pattern of MAVS did not overlap with
that of the ER marker calnexin, indicating that MAVS is
predominantly not an ER protein. To localize the endog-
enous MAVS protein, we used the affinity-purified
MAVS antibody for imaging (Figure S4B). Similar to the
transfected HA-MAVS, the endogenous MAVS also
showed a punctate staining pattern that overlapped
with the staining of cytochrome c, a well-known mito-
chondrial protein. Although the resolution of confocal
microscopy did not allow for the precise localization of
MAVS at the ultrastructural level within the mito-
chondria, these experiments clearly show that MAVS is
localized to the mitochondria.
To further determine if MAVS is localized to the mito-
chondrial membrane, we carried out subcellular frac-
tionation experiments. HEK293 cells were homoge-
nized in an isotonic buffer that preserved mitochondria
and other organelles, and the cell lysates were then
subjected to differential centrifugation to separate nu-
clei, mitochondria, and other organelles as well as cyto-
sol (Figure 7D). MAVS was found in the 5000 × g pellet
(P5), together with other mitochondrial proteins includ-
ing Bcl-xL and cytochrome c oxidase (COX). Immu-
noblotting with an antibody against the endosomal pro-
tein EEA-1 showed that the distribution of this protein
did not correlate with that of MAVS. Similarly, the mark-
ers of endoplasmic reticulum (BiP) and lysosome
(LAMP-1) did not cosegregate with MAVS (data not
shown).
To determine whether MAVS is localized in the outer
or inner mitochondrial membrane, the mitochondrial
fraction (P5) was sonicated to partially rupture the outer
mitochondrial membrane and then fractionated by su-
crose gradient ultracentrifugation (Figure 7D). The soni-
cation released cytochrome c from the intermitochon-
drial membrane space and resulted in a small fraction
of outer mitochondrial membrane floating on the top of
the sucrose gradient, as indicated by immunoblotting
with an antibody against Bcl-xL, which is predomi-
nantly located in the outer mitochondrial membrane.
Under the same condition, the inner mitochondrial
membrane protein COX remained largely in the dense
fractions of the sucrose gradient. Interestingly, a small
fraction of MAVS comigrated with Bcl-xL to the lighter
membrane fractions, suggesting that MAVS colocalizes
with Bcl-xL in the outer mitochondrial membrane. This
conclusion was further supported by our observation
that MAVS and Bcl-xL could be extracted from the
mitochondrial membrane with the same concentration
of Triton X-100 (0.1%), whereas the extraction of COX
requires higher Triton X-100 concentration (0.2%, data
not shown).
Mislocalization of MAVS Impairs Its Function
The aforementioned experiments showed that MAVS is
predominantly localized to the mitochondrial mem-
brane (Figures 7C and 7D), and that removal of the
mitochondrial targeting sequence abolishes its activity
(Figures 7A and 7B). To further examine the importanceof mitochondrial localization for MAVS function, we re-
placed the C-terminal TM domain of MAVS with peptide
sequences that target MAVS to different membrane lo-
cations. These sequences include the CAAX motif from
Rac1 that is known to target fusion proteins predomi-
nantly to the plasma membrane (Michaelson et al.,
2001); the ER targeting sequence from VAMP-2 (vesicle
associated membrane protein-2), which is predomi-
nantly an ER membrane protein (Kim et al., 1999); the
TM sequence from Bcl-2, which is localized in both ER
and mitochondria (Kaufmann et al., 2003); and the TM
sequence from Bcl-xL, which is predominantly in the
mitochondrial outer membrane (Kaufmann et al., 2003).
As shown in Figure 7E, replacement of the TM domain
of MAVS with the analogous domain from Bcl-2 or Bcl-
xL did not impair the ability of MAVS to induce IFN-β.
In contrast, the mislocalization of MAVS to the plasma
membrane (CAAX) or ER (VAMP-2) markedly reduced
the activity of MAVS. Confocal microscopy experiments
confirmed that the majority of MAVS fusion proteins
containing the CAAX or VAMP-2 targeting sequences
were no longer present in the mitochondria, whereas
the fusion proteins containing the Bcl-2 or Bcl-xL tar-
geting sequences were predominantly in the mito-
chondria (Figure S4C). The residual activity (20%–30%
of the wild-type MAVS) may be due to incomplete mis-
localization of the overexpressed MAVS proteins. Taken
together, these results clearly demonstrate the impor-
tance of mitochondrial localization for the signaling
function of MAVS.
MAVS Is Resistant to Detergent Extraction
from Membranes Following Viral Infection
Since we did not detect any difference of MAVS protein
at the level of expression or modification after viral in-
fection, we sought to examine whether the localization
of MAVS changes in response to viral infection. We
found that Sendai virus did not cause the translocation
of MAVS from mitochondria to cytosol (data not
shown). However, when the mitochondrial fraction (P5)
was further extracted with 0.5% Triton X-100, the ma-
jority of MAVS was extracted from mitochondrial mem-
branes isolated from mock-infected cells, but not from
viral-infected cells. In fact, MAVS was even resistant to
extraction with 1% Triton X-100 following viral infection
(data not shown). These results suggest that MAVS
translocates to a detergent-resistant membrane do-
main or particle following viral infection. Further studies
are required to determine the precise location to which
MAVS emigrates and whether this new localization trig-
gers antiviral immune response.
Discussion
In this report, we describe the identification of MAVS
as a novel cellular protein essential for innate immune
defense against viruses. We show that overexpression
of MAVS is sufficient to activate the NF-κB, IRF3, and
IRF7 pathways to induce type-I interferons including
IFN-α and IFN-β, which inhibit viral replication. Con-
versely, silencing of endogenous MAVS expression by
RNAi abolishes the activation of NF-κB, IRF3, and IRF7,
thus blocking the production of interferons and permit-
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(A) MAVS contains a mitochondrial membrane targeting sequence that is essential for signaling. The left panel shows the alignment of the
MAVS transmembrane (TM) sequence with those of known mitochondrial membrane proteins, including proteins of the Bcl-2 family. The
MAVS mutant lacking the C-terminal 30 residues (TM) is illustrated. This mutant or wild-type (wt) MAVS was transfected into HEK293 cells
together with IFNβ-Luc to measure IFN-β induction (right panel).
(B) A MAVS mutant containing the CARD and TM domain is sufficient to activate IFN-β. The MAVS mutants are illustrated on the left panel.
These mutants were transfected into HEK293 cells together with IFNβ-Luc to measure IFN-β induction (right panel).
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(C) MAVS is a mitochondrial protein. pEF-HA-MAVS was transfected into HeLa cells, which were then stained with an HA antibody and imaged
by confocal microscopy. The mitochondria were stained with Mito Tracker. The yellow staining in the overlay image indicates colocalization
of MAVS and Mito Tracker.
(D) Subcellular fractionation of MAVS. HEK293 cells were homogenized in an isotonic buffer and then subjected to differential centrifugation
as shown in the diagram. Different fractions as indicated were analyzed by immunoblotting with antibodies against MAVS, Bcl-xL (outer
mitochondrial membrane), COX (inner mitochondrial membrane), and EEA1 (endosome marker). On the right panel, the crude mitochondrial
fraction (P5) was sonicated to disrupt the outer mitochondrial membrane and then fractionated by sucrose gradient ultracentrifugation. The
fractions were immunoblotted with the indicated antibodies.
(E) Mislocalization of MAVS impairs its function. Expression vectors for the MAVS fusion proteins as indicated on the left panel were trans-
fected into HEK293 cells together with IFNβ-Luc to measure IFN-β induction (right panel). The expression levels and subcellular localization
of the MAVS fusion proteins are shown in Figures S4C and S4D.
(F) MAVS translocates to a detergent insoluble membrane domain following viral infection. The mitochondrial fraction (P5) isolated from
mock- or viral-infected HEK293 cells was resuspended in a buffer containing 0.5% Triton X-100, and the detergent soluble and insoluble
materials were then analyzed by immunoblotting for the presence of MAVS.
(Hockenbery et al., 1990), which has a C-terminal mito-ting viral infection. Epistasis experiments show that
MAVS functions downstream of the viral RNA receptor
RIG-I and upstream of IκB and IRF3 phosphorylation.
MAVS contains an N-terminal CARD-like domain and a
C-terminal mitochondrial membrane-targeting domain,
both of which are essential for MAVS signaling. The
mitochondrial localization of MAVS is particularly inter-
esting, as this is the first example of a mitochondrial
protein playing a pivotal role in innate immunity. To our
knowledge, MAVS is also the first mitochondrial protein
known to activate NF-κB and IRF transcription factors.
The N-terminal CARD-like domain of MAVS likely me-
diates its interaction with other CARD-containing pro-
teins. The logical candidates of MAVS-interacting pro-
teins include the CARD-like domain proteins RIG-I and
MDA-5. Indeed, we were able to detect weak but repro-
ducible binding between MAVS and RIG-I in coimmuno-
precipitation experiments when these proteins were
overexpressed together (Figure S5A). However, we
have not been able to detect any direct interaction be-
tween endogenous MAVS and RIG-I in the presence or
absence of viral infection, nor have we observed trans-
location of RIG-I to the mitochondria following viral in-
fection. Both RIG-I and MDA-5 contain two CARD-like
domains, which may interact with each other intramo-
lecularly, thus preventing their interaction with other
CARD domain proteins. The binding of viral RNA to the
C-terminal RNA helicase domain of RIG-I may induce a
conformational change that allows the tandem CARD
domains of RIG-I to interact with MAVS directly or indi-
rectly. More extensive studies are required to determine
the validity and functional significance of interaction
between RIG-I and MAVS.
How MAVS activates NF-κB and IRF3 is currently un-
known. The NF-κB pathway is primarily regulated by
the activation of IKK, which integrates signals from
multiple pathways. The mechanisms of IKK activation
by extracellular ligands such as TNFα and IL-1β have
been extensively studied (Sun and Chen, 2004). In
these pathways, several proteins including TRAF2,
TRAF6, RIP1, TAK1, and TAB2 have been shown to be
important for IKK activation. We have examined the po-
tential interaction of these proteins with MAVS and
found that only TRAF6 could weakly associate with
MAVS (Figure S5A), presumably through a putative
TRAF6 binding sequence in the proline-rich region of
MAVS (PGENSE, residues 153–158; Ye et al., 2002).ability of MAVS to induce IFN-β (Figure 6B) or NF-κB
(Figure 6C). Furthermore, IFN-β induction by Sendai
virus was not impaired in TRAF6-deficient MEF cells
(Figure S5B). Consistent with our results, Gohda et al.
(2004) have recently shown that TLR3 signaling and
IFN-β induction by LPS are normal in TRAF6-deficient
macrophages. Recently, it has been shown that RIP1
and FADD are involved in viral induction of IFN-β (Ba-
lachandran et al., 2004), raising the possibility that
these proteins mediate signaling by MAVS. However,
we did not detect any interaction between MAVS and
RIP1 or FADD (Figure S5A). Furthermore, the RIP1-defi-
cient MEF cells were fully capable of producing IFN-β
in response to Sendai virus infection (Figure S5B). We
have also been unable to detect any direct interaction
between MAVS and any subunit of the IKK complex,
including IKKα, IKKβ, and NEMO. Thus, it appears that
none of the proteins known to be involved in the classi-
cal pathways of IKK activation is a direct link between
MAVS and IKK activation.
The localization of MAVS to the mitochondria pro-
vides a strategic position to detect viral replication,
which often occurs in intracellular organelles such as
ER. For example, the replication of hepatitis C virus
(HCV) RNA occurs in a membranous web that connects
ER and mitochondria (Rehermann and Nascimbeni,
2005). The HCV core protein has also been found to
reside in the mitochondrial membrane (Schwer et al.,
2004). The dsRNA, which is present in the viral RNA-
protein particles, may recruit the RNA helicase RIG-I
and MDA-5 to the membranous web, allowing these
proteins to interact with MAVS directly or indirectly. The
signal of viral replication may then be transmitted to the
mitochondria, which triggers antiviral responses through
activation of NF-κB and IRF3.
Mitochondria represent the best example of harmoni-
ous symbiosis between the ancient bacteria and
eukaryotic cells. From this bacterial origin, mito-
chondria have further evolved as a sentinel of intrinsic
and extrinsic stress or insults to the cell. The role of
mitochondria in apoptosis is an excellent example of
how mitochondria govern the homeostasis and well-
ness of an organism by regulating cell death in re-
sponse to stress signals (Wang, 2001). Several apo-
ptotic and antiapoptotic proteins are localized to the
mitochondria. The first mitochondrial protein known to
be involved in apoptosis is the protooncogene Bcl-2
Cell
680chondrial transmembrane domain similar to that of
MAVS. In normal cells, the Bcl-2 family of proteins pre-
vents the release of proapoptotic molecules such as
cytochrome c and SMAC/DIABLO from the mito-
chondria to the cytoplasm. In response to an apoptotic
stimulus such as DNA damage, cytochrome c and
SMAC are released to the cytosol to initiate a caspase
cascade leading to cell death. It is not clear whether
MAVS activates NF-κB and IRF3 by mobilizing other
mitochondrial components or through direct interaction
with proteins functioning in the NF-κB and IRF3 path-
ways. Although much more work is required in order to
elucidate the biochemical mechanism of MAVS signal-
ing, our studies have uncovered a new role of mito-
chondria in innate immunity against pathogenic insults
such as viral infection. Thus, mitochondria may have a
central role in integrating signals from pathogenic chal-
lenge and orchestrating an immune or apoptotic re-
sponse depending on the challenge. In this regard,
members in several families of proteins involved in cell
death have recently been shown to function in the im-
munity pathways. Examples of these proteins include
caspase-8/Dredd, IAPs, and paracaspase (e.g, MALT1;
van Oers and Chen, 2005). The CARD domain proteins,
including APAF1, NOD1, NOD2, RIP2, RIG-I and now
MAVS, represent another example of proteins that have
pivotal functions in apoptosis as well as immunity.
MAVS is particularly unique in that it is a CARD domain
protein localized in the mitochondrial membrane, sug-
gesting that it may also be involved in apoptosis. In-
deed, our preliminary studies suggest that RNAi of
MAVS in HEK293 cells led to a partial cleavage of PARP
(POLY (ADP-ribose) polymerase; Figure S6), an early
marker of apoptosis, suggesting that MAVS may pro-
tect cells from apoptosis. Thus, unlike other antiviral
mechanisms that trigger the apoptosis of infected cells
to limit viral spread, MAVS may help the survival of in-
fected cells while mounting a potent interferon re-
sponse to clear viral infection.
We have shown that higher expression of MAVS en-
dows cells with stronger immunity to viral infection,
whereas the loss of MAVS expression renders cells vul-
nerable to viral killing. These results raise the possibility
that variations in the expression levels of MAVS may
endow different individuals with differential immunity
against viral diseases. As many viruses have evolved
to acquire strategies to evade host immunity, it is quite
possible that some viruses may target MAVS in order
to achieve successful infection. In these cases, thera-
pies that enhance MAVS expression or activity may be
a viable option for achieving beneficial immune re-
sponses against viral diseases.
Experimental Procedures
Plasmids and Cell Lines
MAVS sequence was amplified by PCR using the IMAGE clone
5751684 (ATCC) as a template. PCR primers were based on Gen-
Bank accession number BC044952. The open reading frame of
MAVS was cloned into the XhoI and MluI sites of the mammalian
expression vector pEF-IRES-Puro such that N-terminal HA-tagged
MAVS can be expressed under the control of EF1α promoter.
pcDNA3-FLAG-MAVS was constructed by cloning MAVS into the
XhoI and XbaI sites of pcDNA3. Truncated forms of MAVS lacking
either the CARD-like domain (residues 10–77) or the proline-rich
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eegion (residues 103–152) were cloned into pcDNA3 using overlap
xtension PCR. A similar PCR strategy was used to generate MAVS
utants lacking the intervening sequence between the CARD and
M domains (N100 + TM and N200 + TM). To replace the TM do-
ain of MAVS with another domain that targets the fusion protein
o distinct membrane locations, the following sequences were
sed: CAAX (residues 128–148 of Rac1), VAMP-2 (residues 84–116),
cl-2 (residues 208–239), and Bcl-xL (residues 202–233). These se-
uences were fused to the C terminus of MAVS (residues 1–500)
sing overlap extension PCR. Point mutations within the CARD-
ike domain of MAVS were introduced using the QuickChange kit
Strategene). pEF-BOS-FLAG-RIG-I and RIG-I(N) were kindly pro-
ided by Dr. Takashi Fujita (Tokyo Metropolitan Institute of Medical
cience). cDNA encoding amino acids 1–242 of RIG-I was amplified
y PCR and cloned into the XhoI and MluI sites of the baculoviral
xpression vector pFastBac (Invitrogen). For the expression of a
AVS protein fragment containing residues 131–291, the cDNA en-
oding this fragment was inserted into the NdeI and BamHI sites
f pET14b (Novagen). The reporter gene IFNβ-Luc was constructed
y subcloning 110 base pairs of the interferon-β promoter into a
uciferase expression vector. All constructs were verified by auto-
ated DNA sequencing. Plasmids for p-κB3-TK-Luc and pCMV-
acZ have been described previously (Deng et al., 2000). Plasmids
or Gal4-Luc, Gal4-IRF3, Flag-TRIF, Flag-TBK1, and Flag-IKK were
rovided by Dr. Kate Fitzgerald (University of Massachusetts,
orcester) and Dr. Tom Maniatis (Harvard). The IRF7 and IFN-α4-
uc plasmids were from Dr. John Hiscott (McGill University), and
cDNA3-myc-RIP2 was from Dr. Gabriel Nunez (University of Michi-
an). The MEF cell lines deficient in TRAF6, RIP1, and TBK1 were
rovided by Drs. Jun-Ichiro Inoue (University of Tokyo), Michelle
elliher (University of Massachusetts, Worcester) and Wen-Chen
eh (University of Toronto), respectively.
ntibodies and Proteins
he antibodies against RIG-I and MAVS were generated by immu-
izing rabbits with the recombinant proteins His6-RIG-I (1–242) pro-
uced in Sf9 cells and His6-MAVS (131–291) produced in E. coli,
espectively. Both antibodies were affinity purified using the re-
pective RIG-I and MAVS antigen column. Rabbit polyclonal anti-
ody against IRF3 (SC-9082) and NEMO (SC-8330) were purchased
rom Santa Cruz Biotechnology. Monoclonal antibody against IKKβ
BD Bioscience), FLAG (M2; Sigma), HA.11 (Covance), Calnexin
Stressgen), phospho-JNK, and PARP (Cell Signaling) were pur-
hased from the indicated suppliers.
NAi
iRNA oligos at a final concentration of 20 nM were transfected
nto HEK293 cells using the calcium phosphate precipitation
ethod. This transfection procedure was repeated on the second
ay to increase RNAi efficiency. On the third day, cells were trans-
ected with indicated expression plasmids using Lipofectamine
000 reagent (Invitrogen), and harvested 24 hr later. The sequences
f the siRNA oligos are as follows (only the sense strands are
hown): GFP (471–489), GCAGAAGAACGGCAUCAAG; RIG-I (2363–
381), AAUUCAUCAGAGAUAGUCA; MAVSa (899–917), CCACCUU
AUGCCUGUGAA; MAVSb (1364–1382): CAGAGGAGAAUGAGUA
AA. These RNA oligos were synthesized at the UT Southwestern
enter for Biomedical Invention (CBI) facility.
onfocal Imaging
eLa cells were transfected with Polyfect reagent (Qiagen).
wenty-four hours later, cells were trypsinized and plated onto cov-
rslips in 24-well plates. After allowing the cells to adhere for 12–18
r, cells were incubated with 250 nM Mito Tracker Red (Molecular
robes) for 30 min at 37°C. Cells on the coverslips were then
ashed once with PBS and fixed in 3.7% formaldehyde in PBS for
5 min. Cells were permeabilized and blocked for 30 min at room
emperature in a staining buffer containing Triton X-100 (0.2%) and
SA (3%), and then incubated with a primary antibody in the stain-
ng buffer lacking Triton X-100 for 1 hr. After washing three times in
he staining buffer lacking Triton X-100, cells were incubated with
secondary antibody for 1 hr. The coverslips, which were washed
xtensively, were dipped once in water and mounted onto slides
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681using mounting media (VectaShield; Vector Laboratories). Imaging
of the cells was carried out using Zeiss LSM510 META laser scan-
ning confocal microscopy.
Please refer to the Supplemental Data for additional Supplemen-
tal Experimental Procedures.
Supplemental Data
Supplemental Data include six figures and Supplemental Experi-
mental Procedures and can be found with this article online at
http://www.cell.com/cgi/content/full/122/5/669/DC1/.
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